Novo-Nordisk A/S D
D
NVO
43.070
USD
-0.94
(-2.14%)
Post Trading·43.020USD-0.050(-0.12%)
Volume
521,427
EPS
22
Div Yield
4.17
P/E
11
Market Cap
190,323,105,091
Arincen
Market Roundup: What Happened Yesterday and What Awaits Us Today (February 10)
Arincen
Market Roundup: What Happened Yesterday and What Awaits Us Today (February 4)
Arincen
Novo Nordisk Shares Soar as FDA Clears First Weight-Loss Pill
Arincen
Novo Nordisk Cuts 9,000 Jobs as Obesity Drug Battle Intensifies
Arincen
M
R
Europe’s Biggest Companies Fall Further Behind US Rivals
Title: Novo/Nordisk A/S
Sector: Healthcare
Industry: Drug Manufacturers - General
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the world's leading provider of diabetes care products. Based in Denmark, the company manufactures and markets a variety of human and modern insulins for patients with diabetes, as well as injectable and oral GLP-1 therapies, across its obesity and diabetes care segment. Novo also has a rare disease segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.